Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Pedro Herranz's publication output changed over time?
ScholarIQpublication output · 2003–2025
Output grew0% over the shown period — from 1 works in 2003 to 1 in 2025.
1
1
1
3
3
1
1
2003201220162017202020222025
What are the most-cited papers on Pedro Herranz?
ScholarIQmost cited works
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham, Jennifer Clay Cather, Jamie Weisman, David M. Pariser, Eric L. Simpson, Kim Papp, Hyuck-Ki Hong, Diana Rubel, Peter Foley, Errol P. Prens, C.E.M. Griffiths, Takafumi Etoh, Pedro Herranz, Ramón M. Pujol, Jacek C. Szepietowski, Karel Ettler, Lajos Kemény, Xiaoping Zhu, Bolanle Akinlade, Thomas Hultsch, Vera Mastey, Abhijit Gadkari, Laurent Eckert, Nikhil Amin, Neil M.H. Graham, Gianluca Pirozzi, Neil Stahl, George D. Yancopoulos, Brad Shumel
The Lancet. 20171,258 CitationsOPEN ACCESS
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky, Margitta Worm, Charles Lynde, J.‐P. Lacour, Lynda Spelman, Norito Katoh, Hidehisa Saeki, Yves Poulin, Aleksandra Lesiak, Leon Kircik, S.H. Cho, Pedro Herranz, Michael J. Cork, Ketty Peris, Louise Abildgaard Steffensen, B K Bang, Alexandra Kuznetsova, T.N. Jensen, Marie Louise Østerdal, Eric L. Simpson, the ECZTRA 1 and ECZTRA 2 study investigators
British Journal of Dermatology. 2020612 CitationsOPEN ACCESS
Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches
Carlos González‐Herrada, Sara Rodríguez‐Martín, Lucía Cachafeiro, Victoria Lerma, Olga González, José A. Lorente, Antonio Rodríguez, J. González-Ramos, Gastón Roustán, Elena Ramı́rez, Teresa Bellón, Francisco J. de Abajo, Teresa Bellón, Rosario Cabañas, Lucía Cachafeiro, A. García de Lorenzo, J. González-Ramos, Olga Hernández, Pedro Herranz, Elena Ramı́rez, Elena Bravo, Yolanda Alonso, José Antonio Aramburu, Natalia Cámara, Olga González, Carlos González‐Herrada, Olga Laosa, José A. Lorente, Amelia Moscoso, Concepción Payares, Gastón Roustán, Francisco J. de Abajo, Alicia González Quesada, Victoria Lerma, Sara Rodríguez‐Martín
Journal of Investigative Dermatology. 2017144 CitationsOPEN ACCESS
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting
R. Navarro, Eva Vilarrasa, Pedro Herranz, L. Puig, X. Bordas, J.M. Carrascosa, R. Taberner, Marta Ferrán, M. García‐Bustinduy, A. Romero-Maté, R Pedragosa, Amaro García‐Diez, E. Daudén
British Journal of Dermatology. 201299 Citations
Prevalence of mucocutaneous manifestations in 666 patients with COVID‐19 in a field hospital in Spain: oral and palmoplantar findings
A. Nuño‐González, Pilar Martín-Carrillo, K. Magaletsky, M.D. Martin Rios, Cristina Herranz Mañas, J. Artigas Almazan, Gonzalo García de Casasola Sánchez, Emma Castro, Andrea Arenas, Ander Mayor Ibarguren, Marta Feito Rodríguez, B. Lozano‐Masdemont, María Beato, Elena Bravo, Paloma Oliver, María Dolores Montero Vega, Pedro Herranz
British Journal of Dermatology. 202099 CitationsOPEN ACCESS
Related on ScholarIQ
Hospital Universitario La Paz
Institution
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Paper
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
Paper
Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches
Paper
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting
Paper
Prevalence of mucocutaneous manifestations in 666 patients with COVID‐19 in a field hospital in Spain: oral and palmoplantar findings
Paper